Cat. No. 2200
Chemical Name: 6-[[2-(1-Methylethyl)phenyl]]sulfon
Biological ActivityPotent, selective non-peptidic neuropeptide Y1 receptor antagonist (Ki = 48 nM); selective over Y2 and Y5 receptors (Ki > 10 μM). Antagonizes NPY-mediated inhibition of cAMP accumulation in SK-N-MC cells (IC50 = 8.2 nM).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Wielgosz-Collin et al (2002) 8-Amino-5-nitro-6-phenoxyquinolines:potential non-peptidic neuropeptide Y receptor ligands. J.Enz.Inhib.Med.Chem. 17 449.
Wright et al (1996) 8-Amino-6-(arylsulphonyl)-5-nitroquinolines: novel nonpeptide neuropeptide Y1 receptor antagonists. Bioorg.Med.Chem.Lett. 6 1809.
If you know of a relevant reference for PD 160170 please let us know.
Citations are publications that use Tocris products. Selected citations for PD 160170 include:
Zambrano et al (2015) Density of α4β2* nAChR on the surface of neurons is modulated by chronic antagonist exposure. Pharmacol Res Perspect 3 e00111. PMID: 25729578.
Atasoy et al (2012) Deconstruction of a neural circuit for hunger. Physiol Rep 488 172. PMID: 22801496.
Do you know of a great paper that uses PD 160170 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: PD 160170, supplier, Selective, non-peptide, NPY, Y1, antagonists, Neuropeptide, Y, Receptors, PD160170, neuropeptides, Tocris Bioscience, NPY Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Reverse analog of BradykininTASP 0390325
Potent and selective V1B receptor antagonist; orally bioavailableML 233
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonist
June 14 - 17, 2017
Boston, MA, USA